Retatrutide Research Overview

Background: Beyond the Dual Agonist

The GLP-1 receptor agonist class redefined obesity pharmacotherapy — semaglutide achieving ~15% weight loss, tirzepatide (dual GIP/GLP-1) pushing that to ~22%. Retatrutide adds a third receptor to the equation: the glucagon receptor (GCGR). This triple agonism — simultaneously targeting GIPR, GLP-1R, and GCGR — represents the most mechanistically comprehensive single-molecule approach to metabolic disease ever entered into clinical trials. Developed by Eli Lilly (the same company behind tirzepatide), Retatrutide builds on the twincretin platform by adding glucagon receptor activation as a third metabolic input.

The strategic addition of glucagon receptor agonism is counterintuitive at first glance — glucagon is the hormone that raises blood glucose and was traditionally considered diabetogenic. However, at the doses and receptor balance achieved in the Retatrutide molecule, GCGR activation drives hepatic fat oxidation, increases resting energy expenditure (thermogenesis), and promotes brown adipose tissue activation — effects that powerfully amplify the weight loss already produced by GIP/GLP-1 dual agonism. The key is that GLP-1R co-activation counterbalances GCGR's glycaemic effects, neutralising the hyperglycaemia risk while preserving GCGR's potent fat-burning and energy expenditure actions.

24.2%Mean Weight Loss — Phase 2 Peak Dose (48 weeks) 3Receptors Targeted: GIP · GLP-1 · Glucagon 83%Participants Achieving ≥15% Weight Loss at Top Dose

• Developer: Eli Lilly (LY3437943)
• Receptor Targets: GIPR + GLP-1R + GCGR (glucagon receptor)
• Structure: 39-amino acid GIP-based backbone; fatty acid conjugate for weekly dosing
• Half-life: ~Approximately 6 days (once-weekly SC dosing)
• Current Trial Phase: Phase 3 (TRIUMPH programme, as of 2026)
• Peak Clinical Weight Loss: 24.2% mean at 24 mg/week — Phase 2 (NCT04881760)

Triple Receptor Mechanism: How Each Component Contributes

GLP-1R Agonism

Glucose-dependent insulin secretion; glucagon suppression; gastric emptying delay; hypothalamic appetite suppression via NPY/AgRP inhibition and POMC/CART activation. Prevents hyperglycaemia from GCGR activation. The foundational appetite-suppression mechanism shared with semaglutide.

GIPR Agonism

Adipose tissue lipid metabolism regulation; central appetite suppression via hypothalamic GIPR circuits; improved insulin sensitivity in adipocytes; enhanced lean mass preservation during weight loss. The differentiating mechanism tirzepatide established, now incorporated into Retatrutide.

GCGR Agonism

Hepatic fat oxidation; increased resting energy expenditure (thermogenesis); brown adipose tissue activation; reduced hepatic steatosis. The third and novel mechanism — drives caloric expenditure rather than only reducing intake. Counterbalanced by GLP-1R to prevent hyperglycaemia.

The Glucagon Receptor: The Critical Differentiator

Glucagon's traditional role is counter-regulatory — released by pancreatic alpha cells during hypoglycaemia to raise blood glucose via hepatic glycogenolysis and gluconeogenesis. This role has historically made glucagon receptor agonism an unattractive obesity target. The mechanistic insight that unlocked GCGR as a weight loss target was recognising that glucagon's effects extend far beyond glycaemia: GCGR activation in the liver drives fatty acid oxidation (beta-oxidation) and ketogenesis, directly burning stored fat. In adipose tissue, GCGR activation promotes lipolysis and thermogenic gene expression. In brown adipose tissue, GCGR stimulates UCP-1 (uncoupling protein 1) — the molecular thermogenic switch that dissipates energy as heat rather than storing it as ATP.

The net effect of GCGR activation in the Retatrutide context is increased total daily energy expenditure — meaning subjects burn more calories at rest, not just eat fewer. This energy expenditure component is largely absent in GLP-1R and GIP/GLP-1R agonists, which primarily reduce caloric intake. Retatrutide's ability to simultaneously reduce intake (GLP-1R + GIPR) AND increase expenditure (GCGR) creates a dual-sided energy balance intervention that produces weight loss magnitudes exceeding any single-mechanism approach.

Phase 2 Clinical Trial: The Record-Breaking Results

The pivotal Phase 2 Retatrutide trial (NCT04881760) enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) without type 2 diabetes, randomised to one of six dose groups (1, 2, 4, 8, 12, or 24 mg weekly) or placebo over 48 weeks. The results at 48 weeks represented the most dramatic pharmacological weight loss ever documented in a randomised controlled trial at that time.

Mean Body Weight Reduction at 48 Weeks — Phase 2 (NCT04881760) Retatrutide 24 mg/week−24.2% Retatrutide 12 mg/week−22.8% Retatrutide 8 mg/week−17.5% Tirzepatide 15 mg/week (SURMOUNT-1 reference)−22.5% Semaglutide 2.4 mg/week (STEP-1 reference)−14.9% Placebo−2.1%

At the 24 mg dose, 83% of participants achieved at least 15% body weight reduction, and 26% achieved at least 30% weight reduction — outcomes that historically have only been seen with bariatric surgery. Weight loss trajectories had not yet plateaued at 48 weeks, suggesting that longer treatment durations may yield even greater reductions. This non-plateau trajectory at 48 weeks distinguishes Retatrutide from semaglutide (which plateaus by ~68 weeks) and even tirzepatide, and is likely attributable to the sustained energy expenditure-increasing effect of GCGR activation maintaining a persistently elevated caloric deficit.

Comparison Across the GLP-1 Class

• Agent: Semaglutide (Wegovy) — Receptors: GLP-1R — Max Clinical Weight Loss: ~14.9% (STEP-1) — Energy Expenditure Effect: Minimal direct effect — Current Status (2026): FDA approved — obesity, T2DM, sleep apnoea
• Agent: Tirzepatide (Zepbound) — Receptors: GIPR + GLP-1R — Max Clinical Weight Loss: ~22.5% (SURMOUNT-1) — Energy Expenditure Effect: Moderate (GIPR adipose) — Current Status (2026): FDA approved — obesity, T2DM, HFpEF
• Agent: Retatrutide — Receptors: GIPR + GLP-1R + GCGR — Max Clinical Weight Loss: ~24.2% (Phase 2, 48 wks) — Energy Expenditure Effect: Significant (GCGR thermogenesis) — Current Status (2026): Phase 3 — TRIUMPH programme
• Agent: CagriSema — Receptors: GLP-1R + Amylin-R — Max Clinical Weight Loss: ~25.2% (REDEFINE-1) — Energy Expenditure Effect: Moderate — Current Status (2026): Phase 3 / NDA filing anticipated 2026

Hepatic Steatosis and Metabolic Liver Research

An important secondary finding from Retatrutide's Phase 2 data was its pronounced effect on hepatic fat content. MRI-measured liver fat fraction decreased by approximately 80% from baseline in subjects receiving higher Retatrutide doses — a magnitude of hepatic fat reduction that substantially exceeds what has been documented with either semaglutide or tirzepatide at their approved doses. This finding is mechanistically consistent with GCGR's direct hepatic fat oxidation effects and positions Retatrutide as potentially the most powerful pharmacological intervention for metabolic dysfunction-associated steatohepatitis (MASH) studied to date. A dedicated MASH trial is anticipated within the TRIUMPH Phase 3 programme.

Safety and Tolerability

Retatrutide's Phase 2 safety profile was broadly consistent with the GLP-1R agonist class: gastrointestinal adverse effects (nausea, vomiting, diarrhoea) were the most common, predominantly mild to moderate and occurring during the dose-escalation phase. At the 24 mg dose, approximately 45% of participants experienced nausea, 26% vomiting, and 26% diarrhoea — rates somewhat higher than tirzepatide but manageable with the standard gradual dose escalation protocol. No cardiovascular safety signals emerged, and the expected glucose-lowering effects (from GLP-1R activation) were confirmed without significant hypoglycaemia in the non-diabetic population. Importantly, the GCGR component did not produce clinically significant hyperglycaemia, confirming that GLP-1R co-activation effectively counterbalances glucagon's glycaemic effects at the doses studied.

Phase 3 TRIUMPH Programme (2026 Status) > > Retatrutide entered Phase 3 development under Eli Lilly's TRIUMPH programme — a comprehensive cardiovascular outcomes, obesity, type 2 diabetes, and MASH trial package. As of mid-2026, Phase 3 enrolment is ongoing. The cardiovascular outcomes trial (TRIUMPH-CVOT) will be the definitive test of whether Retatrutide's superior weight loss translates to cardiovascular mortality benefits exceeding those demonstrated by tirzepatide's SURPASS-CVOT. If Phase 3 results mirror Phase 2 in magnitude and safety, Retatrutide would be positioned to become the most effective approved pharmacotherapy for obesity ever developed — pending FDA review anticipated in 2027–2028.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Retatrutide (LY3437943) is an investigational compound in Phase 3 clinical trials and is not approved by the FDA or any regulatory agency for human therapeutic use. All efficacy and safety data cited are from Phase 2 investigational trials. This content does not constitute medical advice or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Jastreboff AM, et al. "Triple-hormone-receptor agonist Retatrutide for obesity — a Phase 2 trial." *N Engl J Med*. 2023;389(6):514–526.

1. Coskun T, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept." *Cell Metab*. 2022;34(9):1234–1247.

1. Urva S, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: pharmacokinetics and pharmacodynamics in healthy participants." *Clin Pharmacokinet*. 2022;61(10):1459–1470.

1. Willard FS, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." *JCI Insight*. 2020;5(17):e140532.

1. Day JW, et al. "A new glucagon and GLP-1 co-agonist eliminates obesity in rodents." *Nat Chem Biol*. 2009;5(10):749–757.

1. Drucker DJ. "The biology of incretin hormones." *Cell Metab*. 2006;3(3):153–165.